ATE218883T1 - Verbesserte interferon-polymer konjugate - Google Patents

Verbesserte interferon-polymer konjugate

Info

Publication number
ATE218883T1
ATE218883T1 AT98963947T AT98963947T ATE218883T1 AT E218883 T1 ATE218883 T1 AT E218883T1 AT 98963947 T AT98963947 T AT 98963947T AT 98963947 T AT98963947 T AT 98963947T AT E218883 T1 ATE218883 T1 AT E218883T1
Authority
AT
Austria
Prior art keywords
polymer conjugates
improved interferon
interferon
improved
conjugates
Prior art date
Application number
AT98963947T
Other languages
English (en)
Inventor
Carl W Gilbert
Myung-Ok Park-Cho
Original Assignee
Enzon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25540857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE218883(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Enzon Inc filed Critical Enzon Inc
Application granted granted Critical
Publication of ATE218883T1 publication Critical patent/ATE218883T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT98963947T 1997-12-19 1998-12-16 Verbesserte interferon-polymer konjugate ATE218883T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/994,622 US5951974A (en) 1993-11-10 1997-12-19 Interferon polymer conjugates
PCT/US1998/026677 WO1999032139A1 (en) 1997-12-19 1998-12-16 Improved interferon polymer conjugates

Publications (1)

Publication Number Publication Date
ATE218883T1 true ATE218883T1 (de) 2002-06-15

Family

ID=25540857

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98963947T ATE218883T1 (de) 1997-12-19 1998-12-16 Verbesserte interferon-polymer konjugate

Country Status (23)

Country Link
US (2) US5951974A (de)
EP (1) EP1039922B1 (de)
JP (2) JP3747070B2 (de)
KR (1) KR100607388B1 (de)
AR (1) AR017435A1 (de)
AT (1) ATE218883T1 (de)
AU (1) AU739359B2 (de)
CA (1) CA2268433C (de)
CO (1) CO4870741A1 (de)
DE (1) DE69806055T2 (de)
DK (1) DK1039922T3 (de)
ES (1) ES2178297T3 (de)
HU (1) HU224696B1 (de)
IL (2) IL136290A0 (de)
MY (1) MY119581A (de)
NZ (1) NZ504735A (de)
PE (1) PE20000003A1 (de)
PT (1) PT1039922E (de)
SG (1) SG71179A1 (de)
SI (1) SI1039922T1 (de)
TW (1) TW570802B (de)
WO (1) WO1999032139A1 (de)
ZA (1) ZA9811590B (de)

Families Citing this family (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
CA2296770A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
TR200101086T2 (tr) 1998-10-16 2001-08-21 Biogen, Inc. Interferon beta-1A'nın polimer birleşikleri ve kullanımları.
HK1042098B (zh) 1998-10-16 2009-10-30 拜奥根Idec马萨诸塞公司 干扰素-β融合蛋白及用途
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
PE20001548A1 (es) * 1999-03-02 2001-01-16 Schering Corp Uso de interferon alfa pegilado para el tratamiento de vih-1
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6849254B1 (en) 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
AU7684000A (en) * 1999-10-12 2001-04-23 Santen Pharmaceutical Co. Ltd. Interferon complex and medicinal use thereof
YU32402A (sh) 1999-11-12 2005-03-15 Maxygen Holdings Ltd. Konjugati gama interferona
BR0015506A (pt) 1999-11-12 2002-07-23 Maxygen Holdings Ltd Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças
AU782580B2 (en) 2000-01-10 2005-08-11 Maxygen, Inc. G-CSF conjugates
ATE428445T1 (de) 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
CN1416351A (zh) * 2000-03-09 2003-05-07 先灵公司 Hiv免疫辅助治疗
KR100353392B1 (ko) * 2000-03-13 2002-09-18 선바이오(주) 높은 생체 활성도를 갖는 생체 활성 단백질과 ｐｅｇ의결합체 제조방법
US6476062B2 (en) 2000-03-30 2002-11-05 Schering Corporation Chemokine receptor antagonists
JP2003533537A (ja) * 2000-05-16 2003-11-11 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化
US20040067527A1 (en) * 2000-07-26 2004-04-08 Sara Lavi Intracellular delivery system for protein phosphatases and other polypeptides
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
JP2004508338A (ja) * 2000-09-08 2004-03-18 グリフォン　セラピューティクス，インコーポレーテッド ポリマー修飾合成タンパク質
WO2002026265A2 (en) 2000-09-29 2002-04-04 Schering Corporation Pegylated interleukin-10
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
BR0207576A (pt) 2001-02-27 2004-04-27 Maxygen Aps Variante glicosilada de um polipeptìdeo de interferon beta precursor (ifnb), processos de aumentar a glicosilação in vivo de uma molécula de ifnb precursora, de produzir uma molécula de ifnb glicosilada, para preparar uma variante conjugada e de tratar um mamìfero com esclerose múltiplam composição farmacêutica, molécula de ifnb variante, sequência de nucleotìdeo, vetor de expressão, célula hospedeira de glicosilação conjugado, e, uso de um conjugado
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
KR100508369B1 (ko) * 2001-10-31 2005-08-17 주식회사 바이오폴리메드 펩타이드 스페이서를 갖는 생체적합성 고분자
KR100480429B1 (ko) * 2001-12-04 2005-04-06 선바이오(주) 인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
KR100480430B1 (ko) * 2001-12-04 2005-04-06 선바이오(주) 인터페론-베타와 폴리에틸렌글리콜 유도체의 배합체
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
NZ534708A (en) 2002-01-18 2007-05-31 Biogen Idec Inc Polyalkylene glycol with moiety for conjugating biologically active compound
US7557195B2 (en) * 2002-03-20 2009-07-07 Biopolymed, Inc. Stoichiometric conjugates of biocompatible polymers at the unpaired cysteine residue of the wild-type G-CSF
DK2298278T3 (en) 2002-06-07 2016-02-01 Dyax Corp Prevention and reduction of blood loss and inflammatory response
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
WO2003105768A2 (en) 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
PT1517710E (pt) 2002-06-21 2011-07-08 Novo Nordisk Healthcare Ag Glicoformas do factor vii peguilado
MY140819A (en) 2002-06-28 2010-01-29 Idenix Caymans Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
WO2004005341A2 (en) * 2002-07-03 2004-01-15 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
JP2005537006A (ja) * 2002-08-28 2005-12-08 ダイアックス、コープ 臓器及び組織の保存方法
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
WO2004045648A1 (en) * 2002-11-15 2004-06-03 F. Hoffmann-La Roche Ag Positional isomers of peg ifn alpha 2a
GEP20084487B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
CN102319437B (zh) 2002-12-26 2017-10-13 山景医药公司 具有增强的生物学效用的干扰素‑β的聚合物缀合物
WO2004084949A2 (en) * 2003-03-20 2004-10-07 Xencor Generating protein pro-drugs using reversible ppg linkages
US20060134736A1 (en) * 2003-03-28 2006-06-22 Jacobs John W Human growth hormone conjugated with biocompatible polymer
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
MXPA05010411A (es) * 2003-03-28 2006-05-31 Biopolymed Inc Material activo biologicamente conjugado con polimeros biocompatibles con el complejo 1:1, metodo de preparacion del mismo y composicion farmaceutica que lo contienen.
JP4753867B2 (ja) 2003-04-15 2011-08-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー ヒトｉｌ−１８を含むコンジュゲートおよびその置換変異体
EP1633317A4 (de) 2003-05-16 2008-08-20 Intermune Inc Synthetische chemokin-rezeptor-liganden und anwendungsverfahren dafür
PL3521297T3 (pl) 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
AU2004288128A1 (en) * 2003-07-31 2005-05-19 Anticancer, Inc. The use of PLP with PEG-rMETase in vivo for enhanced efficacy
CN102516386A (zh) 2003-10-10 2012-06-27 诺沃挪第克公司 Il-21衍生物
RS20060259A (sr) 2003-10-14 2008-08-07 Intermune Inc., Makrociklične karboksilne kiseline i acilsulfonamidi kao inhibitori replikacije hcv
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
WO2005042563A2 (en) * 2003-10-22 2005-05-12 Akzo Nobel N.V. Process for incrasing protein pegylation reaction yields by diafiltration ultrafiltration
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US20070258946A1 (en) * 2003-12-23 2007-11-08 Blatt Lawrence M Combination Therapy for Treating Hepatitis C Virus Infection
CN1934143B (zh) * 2004-01-21 2010-10-20 耐科塔医药公司 丙酸封端聚合物的制备方法
CA2553035A1 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
WO2005084303A2 (en) * 2004-03-01 2005-09-15 Enzon Pharmaceuticals, Inc. Interferon-beta polymer conjugates
EP1725583B1 (de) * 2004-03-17 2010-12-01 AntiCancer, Inc. Methoden zur steigerung der protein polyethylenglykol (peg) konjugation
EP1586334A1 (de) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF Konjugate mit PEG
WO2005123113A2 (en) * 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
US20050281872A1 (en) * 2004-06-16 2005-12-22 Peter Summerville Enhanced compliance antiviral medicaments and methods of manufacture and use
JP2008503217A (ja) 2004-06-18 2008-02-07 アンブレツクス・インコーポレイテツド 新規抗原結合ポリペプチド及びそれらの使用
PL2626368T3 (pl) 2004-07-19 2017-06-30 Biocon Limited Koniugaty insulina-oligomer, ich formulacje i zastosowania
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
EP1771573A4 (de) 2004-07-21 2009-02-18 Ambrx Inc Nichtnatürliche kodierte aminosäuren verwendende biosynthetische polypeptide
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US7632491B2 (en) 2004-08-12 2009-12-15 Schering Corporation Stable pegylated interferon formulation
PT3109244T (pt) 2004-09-14 2019-06-04 Gilead Pharmasset Llc ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
BRPI0519170A8 (pt) 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
ATE542920T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Modifiziertes menschliches wachstumshormon
CN102732588B (zh) 2004-12-22 2015-01-07 Ambrx公司 氨酰基-tRNA合成酶的组合物及其用途
BRPI0518661A2 (pt) 2004-12-22 2008-12-02 Ambrx Inc mÉtodos para expressço e purificaÇço do hormânio do crescimento humano recombinante
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
EP2674165B1 (de) 2005-03-31 2016-10-12 The General Hospital Corporation Agonisten für den rezeptor des hepatozyten-wachstumsfaktors zur stimulierung von lymphangiogenese
WO2006133089A2 (en) 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
EP1893632B1 (de) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selektive reduktion und derivatisierung manipulierter faktor vii proteine mit mindestens einem nichtnativen zystein
MX2008001706A (es) * 2005-08-04 2008-04-07 Nektar Therapeutics Al Corp Conjugados de una porcion g-csf y un polimero.
WO2007024535A2 (en) * 2005-08-19 2007-03-01 Wyeth Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
CN101454461A (zh) 2005-11-16 2009-06-10 Ambrx公司 包括非天然氨基酸的方法和组合物
CU23556A1 (es) * 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
US8992905B2 (en) 2006-01-12 2015-03-31 Hokusan Co. Ltd. Oral composition containing interferon-α
ITMI20060612A1 (it) * 2006-03-30 2007-09-30 Keryos Spa New activaded poly-ethylene glycols-and related polymers and their applications
US20070231301A1 (en) * 2006-03-31 2007-10-04 Warren Stephen L Parenteral low dose type 1 interferons for bladder cancer
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
US7632492B2 (en) * 2006-05-02 2009-12-15 Allozyne, Inc. Modified human interferon-β polypeptides
EP2213733A3 (de) 2006-05-24 2010-12-29 Novo Nordisk Health Care AG Analoge des Faktor IX mit verlängerter Halbwertszeit in vivo
US20070282170A1 (en) * 2006-05-30 2007-12-06 Sundaram Ravikumar Rake Retractor and Needle Assembly for Minimally Invasive Surgical Applications
US8008948B2 (en) * 2006-07-06 2011-08-30 Denso Corporation Peak voltage detector circuit and binarizing circuit including the same circuit
EP1886685A1 (de) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methoden, Verwendungen und Zusammensetzungen zur Modulation der Replikation von HCV durch Aktivierung oder Hemmung des Farnesoid X Rezeptors
US20080131398A1 (en) * 2006-08-21 2008-06-05 United Therapeutics Corporation Combination therapy for treatment of viral infections
EP2615108B1 (de) 2006-09-08 2016-10-26 Ambrx, Inc. Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen
WO2008030614A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
JP2010504979A (ja) * 2006-09-29 2010-02-18 カンジ，インコーポレイテッド 遺伝子治療のための方法および組成物
US8679472B1 (en) 2006-10-05 2014-03-25 Merck, Sharp & Dohme Corp. Crystal of human interferon alpha 2B in complex with zinc
KR101079993B1 (ko) * 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
EA018440B1 (ru) * 2006-11-24 2013-08-30 Кадила Хелзкэр Лимитед Композиции конъюгатов пэг-интерферон альфа
CN104163864B (zh) 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
CN101636414B (zh) * 2007-09-04 2012-02-15 厦门伯赛基因转录技术有限公司 聚乙二醇修饰的干扰素α2b及其制备方法和应用
PL2196475T3 (pl) * 2007-09-04 2012-10-31 Biosteed Gene Expression Tech Co Ltd Interferon alfa 2a zmodyfikowany rozgałęzioną cząsteczką glikolu polietylenowego, sposób jego syntezy i zastosowanie
DK2203181T3 (en) * 2007-10-16 2018-05-28 Biocon Ltd An orally administrable solid composition and a method thereof
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
NZ590372A (en) 2008-07-08 2012-09-28 Univ Texas Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
CN102131844B (zh) * 2008-07-31 2016-03-02 药华医药股份有限公司 肽-聚合物缀合物
US20110195912A1 (en) * 2008-09-17 2011-08-11 Nektar Therapeutics Oligomer-Protease Inhibitor Conjugates
HUE035168T2 (en) 2008-09-26 2018-05-02 Ambrx Inc Modified animal erythropoietin polypeptides and their applications
EA201170493A1 (ru) 2008-09-26 2011-10-31 Амбркс, Инк. Микроорганизмы и вакцины, зависимые от репликации неприродных аминокислот
EP3025727A1 (de) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Verfahren zur behandlung von lebererkrankungen
PL2379115T3 (pl) 2008-12-17 2018-03-30 Merck Sharp & Dohme Corp. Wytwarzanie i zastosowania mono- i di-peg il-10
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
NZ617066A (en) 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
JP2012520884A (ja) 2009-03-18 2012-09-10 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー フラビウイルス科ウイルス感染症を治療する方法および組成物
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
EP2805965A1 (de) 2009-12-21 2014-11-26 Ambrx, Inc. Modifizierte Schweine-Somatotropin-Polypeptide und deren Verwendungen
WO2011085103A2 (en) 2010-01-06 2011-07-14 Dyax Corp. Plasma kallikrein binding proteins
CA2791841C (en) 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
ES2644990T3 (es) 2010-03-31 2017-12-01 Gilead Pharmasset Llc Síntesis estereoselectiva de principios activos que contienen fósforo
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
RU2447083C1 (ru) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
SI3572091T1 (sl) 2010-08-17 2024-07-31 Ambrx, Inc., Modificirani polipeptidi relaksina in njihova uporaba
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
CN105713092B (zh) 2011-01-06 2019-09-10 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
CN103930440A (zh) 2011-07-01 2014-07-16 拜耳知识产权有限责任公司 松弛素融合多肽及其用途
WO2013011113A1 (en) 2011-07-20 2013-01-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for determining treatment response in patients infected with hcv genotype 4
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN104066432B (zh) 2011-12-06 2017-06-13 小利兰·斯坦福大学董事会 用于治疗病毒性疾病的方法和组合物
WO2013174988A1 (en) 2012-05-24 2013-11-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and monitoring treatment response in hcv- and hcv/hiv-infected subjects
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
JP6433889B2 (ja) 2012-06-15 2018-12-05 ファイザー・インク Ｇｄｆ−８に対する改善された拮抗抗体およびその使用
ES2611788T3 (es) 2012-06-26 2017-05-10 Sutro Biopharma, Inc. Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
HRP20190878T1 (hr) 2012-08-31 2019-07-26 Sutro Biopharma, Inc. Modificirane aminokiseline koje sadrže azidnu grupu
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
EA021610B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Жидкое противовирусное лекарственное средство
EA021643B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Монопегилированный интерферон-альфа линейной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
EA023360B1 (ru) * 2013-03-28 2016-05-31 Илья Александрович МАРКОВ Линейный ацилазидный пегилирующий агент, способ его получения и способ получения пегилированного интерферона
CA2908198A1 (en) 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
NZ716840A (en) 2013-08-27 2017-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
JP6509867B2 (ja) 2013-08-30 2019-05-08 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためにインターロイキン−１０を使用する方法
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2015070060A1 (en) 2013-11-11 2015-05-14 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP6719384B2 (ja) 2014-03-27 2020-07-15 ダイアックス コーポレーション 糖尿病黄斑浮腫の治療のための組成物および方法
KR20230062688A (ko) 2014-05-01 2023-05-09 아이거 바이오파마슈티컬스 인코포레이티드 델타 간염 바이러스 감염의 치료
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
RU2554761C1 (ru) * 2014-05-13 2015-06-27 Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" Противоэнтеровирусное и иммуностимулирующее средство
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
KR101736870B1 (ko) * 2014-08-20 2017-05-18 한국코러스 주식회사 인터페론 접합체를 포함하는 복합체 및 이의 제조방법
MX2017004838A (es) 2014-10-14 2017-10-16 Armo Biosciences Inc Composiciones de interleucina-15 y usos de estas.
ES2941234T3 (es) 2014-10-22 2023-05-19 Armo Biosciences Inc Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
RS65015B1 (sr) 2014-11-06 2024-01-31 Pharmaessentia Corp Režim doziranja pegiliranog interferona
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
JP2018517673A (ja) 2015-04-21 2018-07-05 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ロナファルニブおよびリトナビルを含む医薬組成物
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
EP4606387A3 (de) 2015-08-25 2025-11-19 Armo Biosciences, Inc. Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und störungen
ES2844629T3 (es) 2015-11-04 2021-07-22 Eiger Biopharmaceuticals Inc Tratamiento de la infección por el virus de la hepatitis delta
KR102857973B1 (ko) 2015-12-11 2025-09-10 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도
CN109328069B (zh) 2016-04-15 2023-09-01 亿一生物医药开发(上海)有限公司 Il-22在治疗坏死性小肠结肠炎中的用途
CN106539557A (zh) * 2016-10-08 2017-03-29 西安交通大学 一种基于恒速静脉输入的药代动力学参数的测定方法
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
NZ752394A (en) 2016-11-14 2021-07-30 Hangzhou Dac Biotech Co Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
ES3009748T3 (en) 2017-01-18 2025-03-31 Inst Nat Sante Rech Med Pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
BR112019016139A2 (pt) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
CN110461354A (zh) 2017-03-29 2019-11-15 瑞华药业集团 蛋白质缀合物
EP3658173A1 (de) 2017-07-25 2020-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur modulation von monozytopoese
RU2678332C1 (ru) 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
PL3849614T3 (pl) 2018-09-11 2024-04-22 Ambrx, Inc. Koniugaty polipeptydu interleukiny-2 i ich zastosowania
CN113366015A (zh) 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
EP3999101A1 (de) 2019-07-18 2022-05-25 ENYO Pharma Verfahren zur verringerung von störeffekten von interferon
EP4090427A1 (de) 2020-01-13 2022-11-23 Takeda Pharmaceutical Company Limited Plasma-kallikrein-inhibitoren und verwendungen davon zur pädiatrischen behandlung von hereditärem angioödem
EP4106794A4 (de) 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd Verfahren zum behandeln der transplant-und-wirts-krankheit
WO2021178612A1 (en) 2020-03-05 2021-09-10 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
AU2021233909A1 (en) 2020-03-11 2022-09-29 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
WO2021228983A1 (en) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
ES2929379T3 (es) 2020-05-20 2022-11-28 Inst Nat Sante Rech Med Métodos para el tratamiento de infecciones por coronavirus
TW202207950A (zh) 2020-06-22 2022-03-01 美商詹森藥物公司 治療d型肝炎病毒感染之組合物及方法
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
EP4199968A1 (de) 2020-08-20 2023-06-28 Ambrx, Inc. Antikörper-tlr-agonist-konjugate, verfahren und verwendungen davon
WO2022043496A2 (en) 2020-08-28 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of mait cells as biomarkers and biotargets in covid-19
WO2022079205A1 (en) 2020-10-15 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ifn-alpha polypeptides for the treatment of coronavirus infections
MX2023011480A (es) 2021-04-03 2023-12-06 Ambrx Inc Conjugados anticuerpo anti-her2-fármaco y usos de estos.
KR20240095442A (ko) 2021-11-03 2024-06-25 항저우 디에이씨 바이오테크 씨오, 엘티디 항체의 특이적 접합

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IT1107772B (it) * 1977-08-22 1985-11-25 Cancer Res Inst Royal Procedimento per la produzione di complessi macromolecolari prodotto ottenuto e composizioni farmaceutiche che lo contengono come ingrediente attivo
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4680338A (en) * 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4810638A (en) * 1986-07-24 1989-03-07 Miles Inc. Enzyme-labeled antibody reagent with polyalkyleneglycol linking group
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ES2085297T3 (es) * 1989-05-27 1996-06-01 Sumitomo Pharma Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada.
DE69017180T2 (de) * 1989-08-07 1995-07-20 Debio Rech Pharma Sa Biologisch wirksame polymere arzneistoffderivate.
AU1676992A (en) * 1991-03-18 1992-10-21 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CA2101361A1 (en) * 1992-08-27 1994-02-28 Robert A. Snow Low diol polyalkylene oxide biologically active proteinaceous substances
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
KR960705579A (ko) * 1993-11-10 1996-11-08 에릭에스. 딕커 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
US5650234A (en) * 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same

Also Published As

Publication number Publication date
IL136290A0 (en) 2001-05-20
AR017435A1 (es) 2001-09-05
PE20000003A1 (es) 2000-01-17
DK1039922T3 (da) 2002-10-14
US6042822A (en) 2000-03-28
KR20010024755A (ko) 2001-03-26
HUP0101532A2 (hu) 2001-08-28
JP3747070B2 (ja) 2006-02-22
JP2005015464A (ja) 2005-01-20
TW570802B (en) 2004-01-11
WO1999032139A1 (en) 1999-07-01
AU739359B2 (en) 2001-10-11
AU1916799A (en) 1999-07-12
HU224696B1 (en) 2006-01-30
MY119581A (en) 2005-06-30
DE69806055T2 (de) 2003-01-23
EP1039922B1 (de) 2002-06-12
NZ504735A (en) 2002-10-25
SG71179A1 (en) 2000-03-21
US5951974A (en) 1999-09-14
PT1039922E (pt) 2002-10-31
KR100607388B1 (ko) 2006-08-02
HUP0101532A3 (en) 2004-08-30
DE69806055D1 (de) 2002-07-18
EP1039922A1 (de) 2000-10-04
CA2268433A1 (en) 1999-06-19
JP2000508356A (ja) 2000-07-04
CA2268433C (en) 2002-07-30
ZA9811590B (en) 1999-06-18
ES2178297T3 (es) 2002-12-16
EP1039922A4 (de) 2000-10-04
CO4870741A1 (es) 1999-12-27
SI1039922T1 (en) 2002-10-31
IL136290A (en) 2008-03-20

Similar Documents

Publication Publication Date Title
ATE218883T1 (de) Verbesserte interferon-polymer konjugate
DK1075281T3 (da) Polyol-IFN-beta-konjugater
PT809996E (pt) Conjugados de interferao
DK0996565T3 (da) Foldelig cykel
DE69824918D1 (de) Sammler
DE69815345D1 (de) Rückspülluftfilteranordnung
ATA93198A (de) Fluoxetinpellets
DE69832228D1 (de) Symmetrierschaltung
DE69814258D1 (de) Phthalocyaninverbindungen
ATA111897A (de) Kimme
NO972868D0 (no) Oligonukleotid-dendrimer konjugater
NO20002555L (no) Skjøt
DE69810884D1 (de) Fluorierungsmischkatalysator
ATE236897T1 (de) 3-benzylpiperidine
NO972738L (no) Solfangerelement
DE69830081D1 (de) Zwischenstück
DE59805449D1 (de) Verdrängerpumpe
FI971594A7 (fi) Liitosjärjestely
FR2770103B1 (fr) Bigoudi perfectionne
ID23663A (id) Persiapan kaprolaktam
ATA46498A (de) Kunststoffgleitbahn
ATA86797A (de) Verschleissschuh
DE59710267D1 (de) Faltschachtel
KR970051665U (ko) 절첩식 자전거
IT1286567B1 (it) Coniugati oligonucleotide-antraciclina o oligonucleotide- antraciclinone

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification